Q1 growth has been broad-based across businesses, says Piramal Pharma chairperson Nandini Piramal

Piramal Pharma chairperson Nandini Piramal said Q1 growth was broad-based across businesses.

Nandini Piramal emphasized the importance of maintaining win rates and converting increased RFP and RFQ activity into commercial orders.

The company's focus is on sustaining growth momentum across its business segments.